Evidence map›Paper›PMID 38877688›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

In vivo effect of LATE-NC on integrity of white matter connections to the hippocampus.

Ashley Heywood, Jane Stocks, Julie A Schneider, Konstantinos Arfanakis, David A Bennett, Mirza Faisal Beg, Lei Wang

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Brain morphometry patterns in the presence of Alzheimer's disease and/or LATE neuropathologic changes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. In vivo effect of LATE-NC on integrity of white matter connections to the hippocampus.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ashley HeywoodDepartment of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.ORCID 0000-0003-0173-990X
Jane StocksDepartment of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Julie A SchneiderRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Konstantinos ArfanakisRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA.
Mirza Faisal BegSimon Fraser University, School of Engineering Science, 8888 University Drive, Simon Fraser University, Burnaby, British Columbia, Canada.
Lei WangDepartment of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS · 1991 to 2020
$49.1M
EPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3M
Rush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7M
RISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4M
Characterizing TDP-43 related hippocampal degeneration and memory loss in agingR01AG067482 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI SCHNEIDER, JULIE A. · 2020 to 2024
$6.8M
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementiaU01NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2023 to 2025
$3.5M
In-vivo MRI-based prediction of TDP43 pathology in agingR01AG064233 · NIA · ILLINOIS INSTITUTE OF TECHNOLOGY · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2019 to 2023
$3.3M
Vascular Cognitive and Motor Decline: Impact of aPLR01AG040039 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARVANITAKIS, ZOE · 2011 to 2015
$2.9M
Neurodegenerative and Neurodevelopmental Subcortical Shape DiffeomorphometryR01EB020062 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI MILLER, MICHAEL I, MOSTOFSKY, STEWART H · 2016 to 2019
$2.8M
PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential DiagnosisR01AG055121 · NIA · OHIO STATE UNIVERSITY · PI ROSEN, HOWARD J, WANG, LEI · 2017 to 2020
$2.8M
Longitudinal validation of cerebral small vessel disease biomarkers in diverse community-based older adults without dementiaUF1NS100599 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI ARFANAKIS, KONSTANTINOS, SCHNEIDER, JULIE A. · 2021 to 2021
$2.5M
Epidemiologic Study of TDP-43 Pathology in Aging and DementiaR01AG042210 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI SCHNEIDER, JULIE A. · 2012 to 2018
$2.4M
National Science Foundation 1636893National Science Foundation 1734853NIA NIH HHS F31 AG079630NIA NIH HHS K23 AG040625NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG040039NIA NIH HHS R01 AG042210NIA NIH HHS R01 AG055121NIA NIH HHS R01 AG064233NIA NIH HHS R01 AG067482NIBIB NIH HHS R01 EB020062NIH HHS 1F31AG079630NIH HHS 3R01AG055121-03S1NIH HHS K23AG040625NIH HHS P30AG10161NIH HHS P30AG72975NIH HHS R01AG040039NIH HHS R01AG042210NIH HHS R01AG055121NIH HHS R01AG064233NIH HHS R01AG067482NIH HHS R01AG15819NIH HHS R01AG17917NIH HHS R01EB020062NIH HHS UF1NS100599NINDS NIH HHS U01 NS100599NINDS NIH HHS UF1 NS100599
6 · The paper itself

Abstract

introductionTAR DNA-binding protein 43 (TDP-43) is a highly prevalent proteinopathy that is involved in neurodegenerative processes, including axonal damage. To date, no ante mortem biomarkers exist for TDP-43, and few studies have directly assessed its impact on neuroimaging measures utilizing pathologic quantification.

methodsAnte mortem diffusion-weighted images were obtained from community-dwelling older adults. Regression models calculated the relationship between post mortem TDP-43 burden and ante mortem fractional anisotropy (FA) within each voxel in connection with the hippocampus, controlling for coexisting Alzheimer's disease and demographics.

resultsResults revealed a significant negative relationship (false discovery rate [FDR] corrected p < .05) between post mortem TDP-43 and ante mortem FA in one cluster within the left medial temporal lobe connecting to the parahippocampal cortex, entorhinal cortex, and cingulate, aligning with the ventral subdivision of the cingulum. FA within this cluster was associated with cognition. DISCUSSION: Greater TDP-43 burden is associated with lower FA within the limbic system, which may contribute to impairment in learning and memory. HIGHLIGHTS: Post mortem TDP-43 pathological burden is associated with reduced ante mortem fractional anisotropy. Reduced FA located in the parahippocampal portion of the cingulum. FA in this area was associated with reduced episodic and semantic memory. FA in this area was associated with increased inward hippocampal surface deformation.

Indexed as

HippocampusWhite MatterAgedAged, 80 and overAlzheimer DiseaseAnisotropyDementiaDiffusion Magnetic Resonance ImagingDNA-Binding ProteinsFemaleHumansMaleTDP-43 ProteinopathiesDNA-Binding ProteinsTARDBP protein, humandiffusion tensor imagingfractional anisotropylimbic‐predominant age‐related TDP‐43 encephalopathy neuropathologic changes (LATE‐NC)magnetic resonance imagingneurodegenerationneuropathology

Identifiers

PMID38877688
PMCPMC11247713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.